Company: RCUS
Filing Date: 2025-02-06
Form Type: 8-K
Source: 0001724521-25-000024
Chunk: 0

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-06
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 6, 2025, in connection with his departure from Gilead Sciences, Inc. (“ Gilead”), Merdad Parsey, M. D., Ph. D., resigned as a member of Arcus Biosciences, Inc.’s (“ Arcus”) Board of Directors (the “ Board”), effective upon the appointment of Gilead’s new director designee pursuant to the Amended and Restated Investor Rights Agreement dated January 29, 2024 by and between Arcus and Gilead. On February 6, 2025, the Board appointed Dietmar Berger M. D., Ph. D., as a Class II director to fill the vacancy left by Dr. Parsey’s resignation. Dr. Berger joined Gilead in January 2025 as their Chief Medical Officer.

Dr. Berger will not receive any compensation for his service as a member of Arcus’s Board. Arcus expects to enter into its standard form of indemnification agreement with Dr. Berger.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              ARCUS BIOSCIENCES, INC.                                     
  Date: February 6, 2025      By:                          /s/ Terry Rosen, Ph. D.        
                                                           Terry Rosen, Ph. D.            
                                                           Chief Executive Officer